Axel Finckh

List of Publications by Year
in descending order

111 papers	9,864 citations	134610 34 h-index	43601 95 g-index
113 all docs	113 docs citations	113 times ranked	9993 citing authors

#	Article	IF	Citations
1	Response to â€˜Correspondence on â€˜Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohortâ€™ by Ruyssen-Witrand<i>et al</i>. Annals of the Rheumatic Diseases, 2023, 82, e33-e33.	0.5	4
2	Response to: â€˜Correspondence on â€˜<i>Prevotella copri</i>in individuals at risk for rheumatoid arthritisâ€™â€™ by Sun and Ni. Annals of the Rheumatic Diseases, 2023, 82, e51-e51.	0.5	0
3	Accounting for missing data caused by drug cessation in observational comparative effectiveness research: a simulation study. Annals of the Rheumatic Diseases, 2022, 81, 729-736.	0.5	6
4	EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Annals of the Rheumatic Diseases, 2022, 81, 780-785.	0.5	12
5	Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study. Clinical Infectious Diseases, 2022, 75, e1037-e1045.	2.9	90
6	Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurology, 2022, 79, 399.	4.5	67
7	Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland. BMJ Open, 2022, 12, e056352.	0.8	2
8	P188â€ƒBaricitinib effectiveness after a previous inadequate response to an alternative JAK inhibitor: results from the Swiss rheumatoid arthritis register. Rheumatology, 2022, 61, .	0.9	0
9	Periodontitis in First Degree-Relatives of Individuals With Rheumatoid Arthritis: A Short Narrative Review. Frontiers in Oral Health, 2022, 3, .	1.2	2
10	Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy. Rheumatology, 2022, 62, 89-97.	0.9	13
11	Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the â€˜JAK-potâ€™ collaboration. Annals of the Rheumatic Diseases, 2022, 81, 1358-1366.	0.5	48
12	Response to: â€˜Non-causal association of gut microbiome on the risk of rheumatoid arthritis: a Mendelian randomisation studyâ€™ by Inamo. Annals of the Rheumatic Diseases, 2021, 80, e104-e104.	0.5	10
13	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Annals of the Rheumatic Diseases, 2021, 80, 36-48.	0.5	153
14	Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries. Annals of the Rheumatic Diseases, 2021, 80, 518-526.	0.5	54
15	Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort. Annals of the Rheumatic Diseases, 2021, 80, 238-241.	0.5	54
16	The impact of seropositivity on the effectiveness of biologic anti-rheumatic agents: results from a collaboration of 16 registries. Rheumatology, 2021, 60, 820-828.	0.9	41
17	Associations between serum antibodies to periodontal pathogens and preclinical phases of rheumatoid arthritis. Rheumatology, 2021, 60, 4755-4764.	0.9	13
18	Identification of biological pathways specific to phases preceding rheumatoid arthritis development through gene expression profiling. International Journal of Immunogenetics, 2021, 48, 239-249.	0.8	1

#	Article	IF	Citations
19	Impact of assessing patient-reported outcomes with mobile apps on patient–provider interaction. RMD Open, 2021, 7, e001566.	1.8	14
20	Primary and secondary non-response: in need of operational definitions in observational studies. Annals of the Rheumatic Diseases, 2021, 80, 961-964.	0.5	18
21	Personalized prediction of disease activity in patients with rheumatoid arthritis using an adaptive deep neural network. PLoS ONE, 2021, 16, e0252289.	1.1	18
22	Cohort profile: SCREEN-RA: design, methods and perspectives of a Swiss cohort study of first-degree relatives of patients with rheumatoid arthritis. BMJ Open, 2021, 11, e048409.	0.8	15
23	Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland. Journal of Clinical Medicine, 2021, 10, 3194.	1.0	8
24	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2021, 80, 1286-1298.	0.5	31
25	Cognitive-bias modification intervention to improve physical activity in patients following a rehabilitation programme: protocol for the randomised controlled IMPACT trial. BMJ Open, 2021, 11, e053845.	0.8	7
26	The Role of Nutritional Factors and Intestinal Microbiota in Rheumatoid Arthritis Development. Nutrients, 2021, 13, 96.	1.7	14
27	Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literature. Therapie, 2021, , .	0.6	1
28	Prediction of sustained biologic and targeted synthetic DMARD-free remission in rheumatoid arthritis patients. Rheumatology Advances in Practice, 2021, 5, rkab087.	0.3	4
29	Analysing and reporting of observational data: a systematic review informing the EULAR points to consider when analysing and reporting comparative effectiveness research with observational data in rheumatology. RMD Open, 2021, 7, e001818.	1.8	4
30	Incidence of COVID-19 in patients treated with infliximab compared with patients treated with rituximab. RMD Open, 2021, 7, e001711.	1.8	6
31	EULAR points to consider for the use of big data in rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2020, 79, 69-76.	0.5	55
32	Mini-Review: Human Microbiome and Rheumatic Diseases. Frontiers in Cellular and Infection Microbiology, 2020, 10, 491160.	1.8	10
33	Associations between gut microbiota and genetic risk for rheumatoid arthritis in the absence of disease: a cross-sectional study. Lancet Rheumatology, The, 2020, 2, e418-e427.	2.2	91
34	Serum calprotectin: a promising biomarker in rheumatoid arthritis and axial spondyloarthritis. Arthritis Research and Therapy, 2020, 22, 105.	1.6	73
35	Predictive factors of treatment persistence in rheumatoid arthritis. Joint Bone Spine, 2020, 87, 531-534.	0.8	5
36	Measuring ACPA in the general population or primary care: is it useful?. RMD Open, 2020, 6, e001085.	1.8	13

#	Article	IF	Citations
37	Preferences for treatments to prevent rheumatoid arthritis in Canada and the influence of shared decision-making. Clinical Rheumatology, 2020, 39, 2931-2941.	1.0	15
38	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.5	1,860
39	Menopause and Possible Effect on Association Between Age and Anticyclic Citrullinated Peptide Antibodies in Women At Risk of Rheumatoid Arthritis. Journal of Rheumatology, 2020, 47, 300.1-300.	1.0	2
40	Is the prevention of rheumatoid arthritis possible?. Clinical Rheumatology, 2020, 39, 1383-1389.	1.0	14
41	Patients with rheumatoid arthritis facing sick leave or work disability meet varying regulations: a study among rheumatologists and patients from 44 European countries. Annals of the Rheumatic Diseases, 2019, 78, 1472-1479.	0.5	7
42	Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations. RMD Open, 2019, 5, e001004.	1.8	30
43	Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution. Rheumatology, 2019, 58, 2221-2229.	0.9	11
44	Preferences of Patients and At-risk Individuals for Preventive Approaches to Rheumatoid Arthritis. Clinical Therapeutics, 2019, 41, 1346-1354.	1.1	28
45	Preventing rheumatoid arthritis: Preferences for and predicted uptake of preventive treatments among high risk individuals. PLoS ONE, 2019, 14, e0216075.	1.1	25
46	Periodontal status correlates with antiâ€citrullinated protein antibodies in firstâ€degree relatives of individuals with rheumatoid arthritis. Journal of Clinical Periodontology, 2019, 46, 690-698.	2.3	43
47	2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Annals of the Rheumatic Diseases, 2019, 78, 1160-1166.	0.5	34
48	The links of hepcidin and erythropoietin in the interplay of inflammation and iron deficiency in a large observational study of rheumatoid arthritis. British Journal of Haematology, 2019, 186, 101-112.	1.2	6
49	<i>Prevotella copri</i> in individuals at risk for rheumatoid arthritis. Annals of the Rheumatic Diseases, 2019, 78, 590-593.	0.5	279
50	FRI0162â€¦BASELINE CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH ANAEMIA IN CLINICAL STUDIES OF TOFACITINIB IN RHEUMATOID ARTHRITIS. , 2019, , .		0
51	AB0274â€¦THE PREDICTIVE VALUE OF RHEUMATOID FACTOR, ANTI-CITRULLINATED PROTEIN ANTIBODIES, ANTI-CARBAMYLATED PROTEIN: ANTIBODIES AND ANTI-PEPTIDYL ARGININE DEIMINASE TYPE-3 ANTIBODIES, ALONE OR IN COMBINATION, ON RADIOGRAPHIC DAMAGE IN RHEUMATOID ARTHRITIS. , 2019, , .		0
52	OP0105â€¦HPR DO MOBILE APPS IMPROVE SHARED DECISION MAKING AND DISEASE MANAGEMENT IN THE RHEUMATIC DISEASES? AN EVALUATION OF APPS IN A SWISS RHEUMATOLOGY REGISTRY. , 2019, , .		2
53	FRI0655â€¦THE IMPACT OF PREGNANCY ON STRUCTURAL PROGRESSION IN PREMENOPAUSAL WOMEN WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
54	SAT0102â€¦ASSOCIATION BETWEEN BASELINE HAEMOGLOBIN LEVELS AND RADIOGRAPHIC JOINT DAMAGE PROGRESSION IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH BARICITINIB OR STANDARD OF CARE. , 2019, , .		1

#	Article	IF	Citations
55	Ultrasound is not associated with the presence of systemic autoimmunity or symptoms in individuals at risk for rheumatoid arthritis. RMD Open, 2019, 5, e000922.	1.8	14
56	Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?. RMD Open, 2019, 5, e000994.	1.8	22
57	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. RMD Open, 2019, 5, e001014.	1.8	73
58	Role of reproductive and menopausal factors in functional and structural progression of rheumatoid arthritis: results from the SCQM cohort. Rheumatology, 2019, 58, 432-440.	0.9	8
59	Glucocorticoid injections for greater trochanteric pain syndrome: a randomised double-blind placebo-controlled (GLUTEAL) trial. Clinical Rheumatology, 2019, 38, 647-655.	1.0	17
60	Response to Tumor Necrosis Factor Inhibition in Male and Female Patients with Ankylosing Spondylitis: Data from a Swiss Cohort. Journal of Rheumatology, 2018, 45, 506-512.	1.0	31
61	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. Annals of the Rheumatic Diseases, 2018, 77, 476-479.	0.5	47
62	Low Hemoglobin and Radiographic Damage Progression in Early Rheumatoid Arthritis: Secondary Analysis From a Phase <scp>III</scp> Trial. Arthritis Care and Research, 2018, 70, 861-868.	1.5	17
63	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. RMD Open, 2018, 4, e000756.	1.8	17
64	EULAR â€˜points to considerâ€™ for the conduct of workforce requirement studies in rheumatology. RMD Open, 2018, 4, e000780.	1.8	16
65	Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. Memorias Do Instituto Oswaldo Cruz, 2018, 113, e170383.	0.8	6
66	Prediction of Real-World Drug Effectiveness Prelaunch: Case Study in Rheumatoid Arthritis. Medical Decision Making, 2018, 38, 719-729.	1.2	8
67	Initial validation and results of the Symptoms in Persons At Risk of Rheumatoid Arthritis (SPARRA) questionnaire: a EULAR project. RMD Open, 2018, 4, e000641.	1.8	17
68	The role of female hormonal factors in the development of rheumatoid arthritis. Rheumatology, 2017, 56, kew318.	0.9	55
69	The prevalence of anticitrullinated protein antibodies increases with age in healthy individuals at risk for rheumatoid arthritis. Clinical Rheumatology, 2017, 36, 677-682.	1.0	20
70	Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers. Annals of the Rheumatic Diseases, 2017, 76, 386-391.	0.5	150
71	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.5	3,366
72	Environmental factors and hormones in the development of rheumatoid arthritis. Seminars in Immunopathology, 2017, 39, 461-468.	2.8	39

#	Article	IF	Citations
73	Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology, 2017, 36, 773-779.	1.0	33
74	Female hormonal factors and the development of anti-citrullinated protein antibodies in women at risk of rheumatoid arthritis. Rheumatology, 2017, 56, 1579-1585.	0.9	63
75	Does addition of glucocorticoids to the initial therapy influence the later course of the disease in patients with early RA? Results from the Swiss prospective observational registry (SCQM). Clinical Rheumatology, 2017, 36, 59-66.	1.0	13
76	Presence of IL-17 in synovial fluid identifies a potential inflammatory osteoarthritic phenotype. PLoS ONE, 2017, 12, e0175109.	1.1	61
77	New viral outbreaks: time for rheumatologists to get involved?. Rheumatology, 2017, 56, 2046-2047.	0.9	1
78	The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis. Arthritis and Rheumatology, 2016, 68, 2141-2150.	2.9	25
79	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. Annals of the Rheumatic Diseases, 2016, 75, 965-973.	0.5	179
80	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. Rheumatology, 2016, 56, kew271.	0.9	22
81	Preventive Treatments for Rheumatoid Arthritis: Issues Regarding Patient Preferences. Current Rheumatology Reports, 2016, 18, 51.	2.1	39
82	Impaired response to treatment with tumour necrosis factor Î± inhibitors in smokers with axial spondyloarthritis. Annals of the Rheumatic Diseases, 2016, 75, 532-539.	0.5	45
83	An Internet-based technique for the identification of persons with symptoms of inflammatory polyarthritis of less than 12 weeks. Clinical Rheumatology, 2015, 34, 465-470.	1.0	6
84	Effectiveness of biologic DMARDs in monotherapy versus in combination with synthetic DMARDs in rheumatoid arthritis: data from the Swiss Clinical Quality Management Registry. Rheumatology, 2015, 54, 1664-1672.	0.9	72
85	87. Comparative Efficacy of Novel Disease-Modifying Antirheumatic Drugs as Monotherapy and in Combination with Methotrexate in Rheumatoid Arthritis Patients with an Inadequate Response to Traditional Dmards: A Network Meta-Analysis. Rheumatology, 2014, 53, i88-i89.	0.9	1
86	The impact of obesity on the development and progression of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1911-1913.	0.5	42
87	Joint Damage Progression in Patients with Rheumatoid Arthritis in Clinical Remission. Do Biologics Perform Better Than Synthetic Antirheumatic Drugs?. Journal of Rheumatology, 2014, 41, 1576-1582.	1.0	31
88	Prevention of Rheumatic Diseases. Rheumatic Disease Clinics of North America, 2014, 40, 771-785.	0.8	19
89	Immune-mediated experimental arthritis in IL-33 deficient mice. Cytokine, 2014, 69, 68-74.	1.4	20
90	Disease activity in rheumatoid arthritis patients at initiation of biologic agents and 1 year of treatment: Results from the Swiss SCQM registry. Joint Bone Spine, 2013, 80, 160-164.	0.8	9

#	ARTICLE	IF	CITATIONS
91	Primary prevention of rheumatoid arthritis: A qualitative study in a high-risk population. Joint Bone Spine, 2013, 80, 673-674.	0.8	25
92	Comparative effectiveness of biologic antirheumatic therapies in rheumatoid arthritis after failure to respond to a first TNF inhibitor. Journal of Comparative Effectiveness Research, 2012, 1, 481-484.	0.6	2
93	EULAR recommendations for terminology and research in individuals at risk of rheumatoid arthritis: report from the Study Group for Risk Factors for Rheumatoid Arthritis. Annals of the Rheumatic Diseases, 2012, 71, 638-641.	0.5	354
94	Evolution of radiographic joint damage in rituximab-treated versus TNF-treated rheumatoid arthritis cases with inadequate response to TNF antagonists. Annals of the Rheumatic Diseases, 2012, 71, 1680.2-1685.	0.5	16
95	Inflammation and autoimmune responses are independent of peripheral MHC class II expression driven by CIITA pIV in collagen induced arthritis. Annals of the Rheumatic Diseases, 2011, 70, A25-A25.	0.5	0
96	Comparative Effectiveness of Rheumatoid Arthritis Therapies. Current Rheumatology Reports, 2010, 12, 348-354.	2.1	3
97	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. Seminars in Arthritis and Rheumatism, 2010, 40, 2-14.e1.	1.6	161
98	Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. Joint Bone Spine, 2010, 77, 313-318.	0.8	34
99	Small studies overestimate the benefit of therapies for OA. Nature Reviews Rheumatology, 2010, 6, 617-618.	3.5	3
100	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Annals of the Rheumatic Diseases, 2010, 69, 1596-1602.	0.5	87
101	Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Research and Therapy, 2009, 11, S1.	1.6	227
102	Early inflammatory arthritis versus rheumatoid arthritis. Current Opinion in Rheumatology, 2009, 21, 118-123.	2.0	22
103	Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents. Annals of Internal Medicine, 2009, 151, 612.	2.0	86
104	At the horizon of innovative therapy in rheumatology: new biologic agents. Current Opinion in Rheumatology, 2008, 20, 269-275.	2.0	32
105	B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents. Arthritis and Rheumatism, 2007, 56, 1417-1423.	6.7	192
106	Anti–Cyclic Citrullinated Peptide Antibodies in the Diagnosis of Rheumatoid Arthritis: Bayes Clears the Haze. Annals of Internal Medicine, 2007, 146, 816.	2.0	15
107	Short-Term Efficacy of Intravenous Pulse Glucocorticoids in Acute Discogenic Sciatica. A Randomized Controlled Trial. Spine, 2006, 31, 377-381.	1.0	73
108	The effectiveness of anti–tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: A population-based study. Arthritis and Rheumatism, 2006, 54, 54-59.	6.7	72

#	Article	IF	Citations
109	Performance of an automated computer-based scoring method to assess joint space narrowing in rheumatoid arthritis: A longitudinal study. Arthritis and Rheumatism, 2006, 54, 1444-1450.	6.7	34
110	Occupational silica and solvent exposures and risk of systemic lupus erythematosus in urban women. Arthritis and Rheumatism, 2006, 54, 3648-3654.	6.7	89
111	Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. Arthritis and Rheumatism, 2006, 55, 864-872.	6.7	410